S64
29.9.2022 14:40:15 CEST | Business Wire | Press release
S64, the trusted alternatives partner to the world’s leading asset managers and private banks, has today announced a series of strategic hires following a period of rapid growth since its launch in 2020.
S64’s best-in-class team, who worked together for over a decade at Deutsche Bank, has further strengthened its expertise by making a number of appointments from blue-chip institutions to its London office. The business also has plans to advance its footprint across EMEA, Asia and Australia in major global financial hubs.
Strategic hires following rapid growth
Led by founder and CEO Tarun Nagpal, S64’s team has led the way in industry innovation for more than a decade, pioneering the development of alternative platform solutions. The latest additions include Venkata Kota, Head of Client Solutions, formerly of Goldman Sachs and Deutsche Bank; Richard Marland, Head of Operations and Fund Governance, formerly of Deutsche Bank; Tetyana Turek, Business and Project Management, formerly of Deutsche Bank; Mark Slater, Legal Counsel and Compliance, formerly of J.P. Morgan and Simmons & Simmons; and Eve Wachtel, Asia Pacific Distribution, formerly of Deutsche Bank.
The firm’s structuring and solutions team also boasts three new additions, comprising Matteo De Checchi, Dennis Bews and Adam Hooper, from Deutsche Bank, Credit Suisse and Barings respectively.
S64 expects to more than double its 40-strong headcount over the next 12 months across its structuring, distribution, platform and technology expertise.
Tarun Nagpal, CEO of S64, commented: “I’m delighted to welcome some of the industry’s leading talent to our firm. Not only do they bring with them deep technical experience, but a track record of market-defining innovation.
We are witnessing a revolution in how private markets are accessed. Our award-winning legacy, unique proposition and market-leading expertise mean we are well-positioned to build upon our impressive growth to date.
As we define a new era in alternative assets, we plan to deepen our expertise through further strategic hires and expand our presence into target markets over the coming year.”
Pipeline of mandates with platinum-level clients
S64 is already the trusted partner of global leaders across private equity, asset management and private wealth having won numerous competitive mandates, including the majority of the top 10 largest private markets managers globally, who have raised over $750 billion USD of funds in the past decade. The firm has built market share at speed with a robust pipeline of new opportunities.
The business is leading the way in industry innovation through the development of an array of novel solutions for clients, including the structuring, delivery and servicing of ELTIFs, UK LTAFs, and open-ended semi-liquid retail products, helping them rapidly scale their offerings.
Tarun Nagpal added: “We’re excited to be working with platinum-level asset managers and private banks, having won a pipeline of highly-coveted mandates which has turbocharged our ambitious growth trajectory.
With our world-class proprietary technology, which services the full lifecycle of alternatives products, our innovative approach is further opening up access to private markets and enabling them to flourish.”
ENDS.
Notes to Editors
- Global fund manager ranking and fundraising amount according to Preqin’s Fund Managers League Table as of 25.09.22.
- Preqin calculates top global fund managers based on aggregate capital raised via closed-end commingled funds.
- Fundraising amount is based on funds raised in the last 10 years.
About S64
S64 is a leading global alternatives solutions business bridging the opportunity in private markets. It works with the world’s first-class asset managers and private banks across private equity, credit, real estate, infrastructure and impact to develop innovative solutions for private banks and wealth managers.
S64’s innovative technology platform offers the full lifecycle management of alternative assets — from structuring and onboarding to financing, as well as secondary market capabilities.
Its team draws on an award-winning legacy in fund and product solutions, digital innovation and international distribution, having pioneered alternative investment platforms for over a decade.
www.s64capital.com | LinkedIn | Twitter
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220929005482/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
